The Role of Intestinal Microbiota and Probiotics Supplementation in Multiple Sclerosis Management

Nima Hasaniani1, Seyed Mostafa Rahimi2, Marziyeh Akbari3

  • 1Student Research Committee, Babol University of Medical Sciences, Babol, Iran; Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.

Neuroscience
|May 22, 2024
PubMed

Insights

Probiotic supplements show promise for managing multiple sclerosis (MS) by positively influencing the gut microbiome and its connection to the central nervous system (CNS). This approach supports gut health and immune function in MS patients.

Area of Science:

  • Neuroimmunology
  • Microbiome Research
  • Gastroenterology

Background:

  • Multiple sclerosis (MS) is an autoimmune neurological disorder with complex genetic and environmental causes.
  • The gut microbiome plays a significant role in MS pathogenesis via the gut-brain axis (GBA).
  • Modulating gut microbiota is a key strategy for managing neurological disorders like MS.

Purpose of the Study:

  • To explore the influence of the gut microbiome on the central nervous system (CNS).
  • To investigate the potential of probiotic supplements as a therapeutic strategy for MS.
  • To elucidate the mechanisms by which probiotics impact MS.

Main Methods:

  • Review of current research on gut microbiota and MS.
  • Analysis of the role of probiotics in modulating the gut-brain axis.
  • Examination of studies involving probiotic use in MS patients.

Main Results:

  • Gut microbiota significantly impacts the CNS.
  • Probiotics reinforce gut barrier function and modulate immune responses.
  • Probiotics influence neurotransmitter function and host resistance to pathogens.
  • Evidence suggests potential therapeutic benefits of probiotics in MS management.

Conclusions:

  • The gut microbiome is a critical factor in CNS health and MS.
  • Probiotic supplementation is a promising avenue for MS treatment.
  • Probiotics offer multifaceted benefits including immune modulation and gut barrier enhancement.

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
126
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
195
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
268
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160